Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeracyteVCYT -4.15%80 3-Year Book Growth Rate is 3.40% as of Jun. 2026, which is 76% below its 10-year median of 14.35. GuruFocus rates VCYT with a GF Score™ of 80/100 and a GF Value™ of $38.87 (Fairly Valued). The stock has 4 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Veracyte ranks better than 65.8% on this metric.
During the past 12 months, Veracyte's average Book Value per Share Growth Rate was 11.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 3.40% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 12.20% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 34.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Veracyte was 99.10% per year. The lowest was -16.00% per year. And the median was 14.35% per year.
Veracyte (NAS:VCYT) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Veracyte 3-Year Book Growth Rate Related Terms
VCYT vs GRAL, ADPT, CDNA: 3-Year Book Growth Rate Comparison
For the Diagnostics & Research subindustry, Veracyte's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte 3-Year Book Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Veracyte's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 3.40% mean?
Veracyte (VCYT) has a 3-Year Book Growth Rate of 3.40% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Veracyte and its competitors. This is 76% below median its historical median of 14.35. According to the industry distribution chart, Veracyte ranks #66 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 34.2%.
Is Veracyte's 3-Year Book Growth Rate too high?
Veracyte's current 3-Year Book Growth Rate of 3.40% is 76% below median its 10-year median of 14.35. Based on the distribution chart, Veracyte ranks #66 out of 193 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Veracyte has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's 3-Year Book Growth Rate compare to GRAL and ADPT?
According to the Medical Diagnostics & Research industry distribution chart, Veracyte ranks #66 out of 193 companies for 3-Year Book Growth Rate. This puts Veracyte in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Diagnostics & Research company?
A good 3-Year Book Growth Rate depends on the Medical Diagnostics & Research industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Veracyte and its competitors. Veracyte's current 3-Year Book Growth Rate is 3.40%, which is 76% below median its own 10-year median of 14.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Fairly Valued. The stock's GF Value™ is $38.87, compared to a current price of $42.80 — trading 10.1% above its estimated fair value. The current 3-Year Book Growth Rate is 3.40%, which is 76% below median its 10-year median of 14.35. Veracyte's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Veracyte (VCYT), the current 3-Year Book Growth Rate is 3.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veracyte (VCYT) Overvalued in 2026?
Based on GuruFocus' analysis, Veracyte stock appears to be overvalued.
The current stock price of $42.80 is trading 10.1% above its estimated GF Value™ of $38.87.
GuruFocus considers Veracyte to be Fairly Valued.
Key valuation signals for VCYT:
3-Year Book Growth Rate: 3.40% (76% below median its 10-year median of 14.35)
GF Value™: $38.87 vs. price of $42.80 (10.1% above fair value)
No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
80GF Score
Get the complete analysis for VCYT
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCYT has been successfully added to your 
